8059 —Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
Introduction: Endocrine therapies (ETs) are associated with alopecia (EIA) in 15-25% of patients. There are no approved therapies for EIA. The purpose of this review is to provide dermatologists and oncologists with a foundation for the practical understanding of 5 α-reductase inhibitors and spironolactone for breast cancer patients and survivors with alopecia attributed to ETs, including the effect of these treatments on sex hormone levels, any reported drug interactions, and any risk of malignancy.
Background: Persistent hair disorders resulting from cytotoxic or endocrine agents used in early stages of breast cancer such as alopecia, hirsutism, and madarosis develop in 4-35% of patients, however their impact on quality of life (QoL) has not been reported. The CHANCE study is a prospective, longitudinal study of chemotherapy- and endocrine therapy-induced hair, skin, and nail changes in women with nonmetastatic breast cancer. This preliminary analysis intends to evaluate the impact of permanent hair sequelae of adjuvant breast cancer therapies on patients ’ QoL.
ConclusionAdjuvant treatment with docetaxel (CD ≥ 400 mmg/m2) is associated with a significant rate of grade 2 PA, leading to wearing a wig, in around 10% of patients. This toxicity was completely prevented with scalp cooling. Clinical Trial Reference: NCT00515762.
Breast cancer patients are at risk for alopecia with endocrine therapy, but hair growth can often be restored with topical minoxidil.Medscape Medical News
A study, published inJAMA Dermatology, reports that endocrine therapy-induced alopecia in breast cancer patients is mechanistically similar to androgenetic alopecia.Medical Xpress
92 percent had grade 1 severity alopecia with endocrine tx; pattern similar to androgenetic alopecia
THURSDAY, April 12, 2018 -- For patients with breast cancer, endocrine therapy-induced alopecia (EIA) has a pattern that is similar to androgenetic alopecia, according to a study published online April 11 in JAMA Dermatology. Azael Freites-Martinez,...
This cohort study describes clinical features, quality of life, and response to minoxidil among female patients with breast cancer who have endocrine therapy –induced alopecia.
Background: Maintenance of quality of life (QoL) is one of the main aims of treatment of incurable diseases such as metastatic breast cancer (MBC). In patients with HER2-positive MBC, taxan-based chemotherapy in combination with dual HER2 targeted therapy with trastuzumab and pertuzumab has shown promising efficacy results in terms of prolonged survival. However, cytostatic treatment is often accompanied by adverse events of grade 3 or higher, seriously impacting the patients' QoL. In patients with HER2-positive and hormone-receptor positive MBC, the combination of trastuzumab with aromatase inhibitors was shown to be a sa...
Abstract Patients diagnosed with breast cancer may have supportive care needs for many years after diagnosis. High quality multidisciplinary care can help address these needs and reduce the physical and psychological effects of breast cancer and its treatment. Ovarian suppression and extended endocrine therapy benefits are associated with vasomotor, musculoskeletal, sexual and bone density-related side effects. Aromatase inhibitor musculoskeletal syndrome is a common reason for treatment discontinuation. Treatment strategies include education, exercise, simple analgesia and a change to tamoxifen or another aromata...